Bioinformatic and clinical experimental assay uncovers resistance and susceptibility mechanisms of human glioblastomas to temozolomide and identifies new combined and individual survival biomarkers outperforming promoter methylation

Bioinformatic and clinical experimental assay uncovers resistance and susceptibility mechanisms of human glioblastomas to temozolomide and identifies new combined and individual survival biomarkers outperforming promoter methylation

Background: Glioblastoma (GBM) is the most aggressive and lethal central nervous system (CNS) tumor. The treatment strategy is mainly surgery and/or radiation therapy, both combined with adjuvant temozolomide (TMZ) chemotherapy. Historically, methylation of MGMT gene promoter is used as the major bi...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander Modestov, Marianna Zolotovskaia, Maria Suntsova, Galina Zakharova, Aleksander Seryakov, Ivana Jovcevska, Jernej Mlakar, Elena Poddubskaya, Aleksey Moisseev, Grigory Vykhodtsev, Sergey Roumiantsev, Maksim Sorokin, Victor Tkachev, Aleksander Simonov, Anton Buzdin
Format: Article
Language:English
Published: SAGE Publishing 2024-11-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359241292269
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17588359241292269

Similar Items